{"entity":{"id":"patrick-schoffski","kind":"person","name":"Patrick Schöffski","aka":[],"tldr":"Leuven oncologist who led the trial that showed eribulin lengthens survival in advanced liposarcoma, the basis of the drug's approval for that disease.","summary":"Patrick Schöffski heads general medical oncology at UZ Leuven and chairs the EORTC soft tissue and bone sarcoma group's early-phase work. He was first author of the 2016 Lancet report of the phase 3 trial in which eribulin improved overall survival compared with dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma, with the benefit concentrated in liposarcoma, leading to eribulin's approval for that indication.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Patrick_Sch%C3%B6ffski","links":[],"tags":["sarcoma","trialist"],"related":[],"cancers":["liposarcoma","leiomyosarcoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uz-leuven"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-eribulin-liposarcoma-schoffski-lancet-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of General Medical Oncology, UZ Leuven and Leuven Cancer Institute","institutionId":"uz-leuven","specialisms":["Soft tissue sarcoma","Early-phase drug development","Rare cancers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sch%C3%B6ffski%5BAuthor%5D"}],"papers":[]},"route":"/people/patrick-schoffski/","neighbours":{"cancer":[{"id":"leiomyosarcoma","kind":"cancer","name":"Leiomyosarcoma","route":"/cancers/leiomyosarcoma/"},{"id":"liposarcoma","kind":"cancer","name":"Liposarcoma","route":"/cancers/liposarcoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"institution":[{"id":"uz-leuven","kind":"institution","name":"UZ Leuven / Leuven Cancer Institute","route":"/institutions/uz-leuven/"}],"paper":[{"id":"paper-eribulin-liposarcoma-schoffski-lancet-2016","kind":"paper","name":"Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma","route":"/key-papers/paper-eribulin-liposarcoma-schoffski-lancet-2016/"}]}}